Prosthetic joint infections caused by Mycobacterium avium complex: a series of five cases

Katharine Dobos¹, Gina A. Suh², Aaron J. Tande², and Shanthi Kappagoda¹

¹Division of Infectious Diseases and Geographic Medicine, Stanford School of Medicine, Stanford, CA 94304, USA
²Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN 55902, USA

Correspondence: Shanthi Kappagoda (skappago@stanford.edu)

Received: 20 March 2022 – Revised: 31 May 2022 – Accepted: 9 June 2022 – Published: 6 July 2022

Abstract. Prosthetic joint infection (PJI) due to Mycobacterium avium complex (MAC) is a rare entity. There is limited guidance on management strategies and outcomes. In this paper, we describe the demographics, comorbidities, and clinical course of five patients at two academic institutions, constituting the largest series described to date.

1 Introduction

Mycobacterium avium complex (MAC) historically represents a rare cause of prosthetic joint infection (PJI), although it remains an important pathogen to consider in routine clinical practice. Patients with immune suppression have improved survivorship and clinical stability enabling them to pursue elective orthopedic interventions, and molecular laboratory techniques have advanced to identify atypical and fastidious pathogens. Guidelines for treatment of pulmonary nontuberculous mycobacteria and PJI provide little information on how to manage PJIs caused by MAC (Daley et al., 2020; Osmon et al., 2013). Among case reports published in the literature, all of the patients reported have a comorbid immune-suppressing condition, including treated rheumatoid arthritis (RA) (Ingraham et al., 2017; Sigler and Newman, 2019), solid organ transplantation (Gupta and Claus, 2009), hematologic malignancy (Sixt et al., 2020; Tan et al., 2016), and HIV/AIDS (McLaughlin et al., 1994). Here, we present a case series of five patients treated at two institutions with PJI caused by MAC who were treated at our respective institutions. Cases of MAC PJI between 1 January 2001 and 1 June 2021 were identified. All patients over the age of 18 years who underwent treatment for MAC PJI at our institutions were included. Medical and surgical therapies were not standardized and were performed at the discretion of the treating medical/surgical teams. The patient outcomes were followed until documentation of patient death, clinical cure, or failure to follow up at our institution. PJI was diagnosed based on provider clinical judgment at the time of intervention and was retrospectively confirmed using Musculoskeletal Infection Society (MSIS) 2011 criteria (Workgroup Convened by the MSIS, 2011). In one case, given the relative paucity of pathology and cultures available from the prosthetic joint, the diagnosis was made based on a single positive periprosthetic culture with characteristic gross operative findings combined with positive cultures from other sites in the context of disseminated infection.

3 Results

The most common comorbidity among patients in our series was RA on therapy, diagnosed in three of the five patients in the series (see Table 1). Four of the five patients met MSIS 2011 (Workgroup Convened by the MSIS, 2011) criteria for PJI based on the presence of two or more positive cultures obtained from the affected prosthetic joint (see Ta-
ble 2). However, we note that patient no. 5 presented with abnormal joint aspirate parameters, which may have been impacted by background hematologic derangements, and elevated inflammatory markers suspected to be confounded by active hematologic malignancy. Patient no. 4 did not clearly meet MSIS criteria but was diagnosed by means of a single positive joint aspirate culture and compelling clinical symptoms in the context of confirmed disseminated MAC.

Among the patients in our series who underwent treatment for MAC PJI, all patients but one underwent combined medical and surgical therapy, as described in Table 2. Surgical therapy included arthroplasty resection in three patients, with two of those patients ultimately undergoing reimplantation arthroplasty. Per surgeon discretion, a spacer was not used in one patient with resection in the context of unclear benefit given preoperative diagnosis of MAC; furthermore, the patient was not anticipated to be a reimplantation candidate due to poor bone stock and surgical risk. One patient underwent debridement with modular component (femoral head and polyethylene liner) exchange. Surgery was deferred due to medical contraindications in one patient. Medical therapy included at least 12–16 months of triple-antibiotic therapy with a rifamycin, ethambutol, and macrolide in all patients, with the extension of therapy to lifelong suppression in the patient with disseminated disease. Clinical cure was achieved in three of five patients at the time of the follow-up, which ranged from 4 months to 7 years. Three of five patients treated had MAC isolates documented to be clarithromycin susceptible at the time of initiation of triple-antibiotic therapy with macrolide backbone. The clarithromycin minimum inhibitory concentration (MIC) was unknown in the remaining two.

4 Discussion

To date, the literature has described six cases of individuals who experienced PJI due to MAC, all of whom were considered to be immunosuppressed (Gupta and Clauss, 2009; Ingraham et al., 2017; McLaughlin et al., 1994; Sigler and Newman, 2019; Sixt et al., 2020; Tan et al., 2016). In our case series, the majority of patients (three out of five) were undergoing treatment for RA, one patient had a history of systemic lupus erythematosus (SLE) and subsequent hematologic malignancy, and one patient did not have a documented immunosuppressing risk factor for the development of MAC PJI. This raises the question of whether this patient possessed an undiagnosed immunologic deficiency which increased the risk of MAC infection, and similar cases may benefit from a formal immunology evaluation. Alternatively, there may have been a unique exposure with high inoculum load that placed this patient at risk of infection which was not captured in the medical history. Another interesting finding in this series is the absence of documented disseminated or multi-organ disease among the patients with MAC PJs; only one of the five patients was noted to have concurrent MAC pulmonary nodular bronchiectatic (as well as native vertebral) disease. There was a wide range of prosthesis ages at the time of MAC PJI diagnosis, with a minimum of 4 months and a maximum of 26 years postoperatively, which suggests that the mechanism of inoculation may have been different among the patients described, with earlier manifestation suggesting possible introduction at time of surgery and later manifestations potentially related to hematogenous or direct traumatic seeding after an environmental exposure. In three of the five cases, MAC was the sole pathogen isolated in the orthopedic cultures. While this could raise suspicion for MAC being a contaminant rather than true pathogen, four of the patients in this series had multiple periprosthetic cultures positive for MAC (except for the patient with disseminated infection, who had a single positive culture from the affected prosthetic joint but numerous positive cultures from other sites of infection).

There was a range of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) values as well as joint fluid cell counts at the time of diagnosis, although the limited availability of a full range of data from joint aspirations preoperatively (only available for one of the five patients) makes extrapolation of the significance of this finding challenging. Of the patients who did have documented cell counts with their aspirations, only one out of the three had an elevated synovial fluid white blood cell (WBC) count and elevated PMN (polymorphonuclear leukocyte) percentage according to the 2011 MSIS criteria. Our case series shows that there can be heterogeneity in inflammatory markers and joint aspirate parameters among patients ultimately diagnosed with MAC PJI, which could be related to the severity or acuity of infection, underlying host hematologic and immunologic factors, and concurrent use of immunomodulating therapies. Outcomes among patients in our series were generally positive, with a combination of surgical management as well as prolonged (12–16 month) combination antimycobacterial therapy similar in duration to that recommended for pulmonary disease (Daley et al., 2020). However, one patient experienced another episode of PJI due to an unrelated organism after apparent cure of MAC PJI, another patient later died of an unrelated cause while remaining on suppressive MAC therapy due to disseminated disease, and yet another patient succumbed to their hematologic malignancy. This would, unsurprisingly, suggest that there is a high risk of morbidity and mortality in patients with MAC PJI due to comorbidities with MAC infection reflecting underlying host factors.

As techniques for making the diagnosis of PJI evolve, including the increasing use of molecular methods for pathogen diagnosis (which may improve the rapidity of the diagnosis of slower-growing pathogens such as MAC), we anticipate that there will be an increasing number of cases of MAC PJI described in the literature. We hope this will facilitate the development of a more cohesive strategy to iden-
Table 1. Demographic data related to five cases of MAC PJI.

| Patient | Age (a) | Sex | Site | Risk factors for MAC infection | Clinical presentation/Concurrent MAC pulmonary infection or disseminated disease | Age of prosthesis (b) | ESR (mm h\(^{-1}\)) at time of diagnosis | CRP (mg/dL\(^{-1}\)) at time of diagnosis | Number of positive cultures for MAC |
|---------|---------|-----|------|--------------------------------|--------------------------------------------------------------------------------|----------------------|----------------------------------------|----------------------------------------|---------------------------------|
| 1       | 70/M    | L   | knee | None apparent                   | Joint pain after initial knee replacement led to revision for presumed aseptic loosening 4 years after index surgery, followed by second revision with liner exchange 6 years after index surgery. Persistent symptoms with negative cultures and inflammatory cell counts (no AFB cultures sent) prompted explantation and spacer placement 8 years after index surgery: one intraoperative culture was positive for MAC, felt to be a contaminant, and not treated. Patient was referred to our institution and had spacer exchange 9 years following index surgery with isolation of MAC on all three intraoperative cultures prompting treatment. Patient was treated for MAC for 8 months prior to having reimplantation done. Patient completed an additional 8 months of MAC therapy after reimplantation. | N 9 years from index surgery; 4 months from last revision | 11                                      | 0.7                                         | One intraoperative (thought to be a contaminant), one preoperative aspiration, three of three intraoperative cultures |
| 2       | 67/F    | R   | hip  | RA treated with methotrexate and leflunomide, prior prednisone use remotely | Patient presented with 3 years of hip pain after a fall. ESR and CRP were elevated, and the aspiration sent to rule out PJI grew MAC (fluid obtained was of insufficient quantity for cell count). Due to concern that this could be a contaminant, the aspiration was repeated 2 months later and again grew MAC. Resection arthroplasty was done: 2 months later with MAC on intraoperative AFB culture. | N 26 years from index surgery; 19 years from last revision | 80                                      | 4.6                                         | One preoperative aspiration, one of one intraoperative |
| 3       | 74/M    | R   | knee | RA and OA, prior prednisone use discontinued after colonic perforation approx. 1 month after MAC diagnosis | Patient underwent index R TKA at another institution with poor postoperative recovery. Aspiration done 3 months after index surgery showed WBC > 25,000, culture negative (AFB not sent). MRI of the knee 5 months after index surgery showed a loculated cystic mass, and repeat aspiration of the knee and the cyst grew MAC at this time. At the time of resection arthroplasty, 9 months from index TKA, intraoperative cultures grew MAC in two of two AFB cultures and *Actinomyces naesloeni* in two of five aerobic cultures. Patient was treated for MAC for 8 months prior to having reimplantation done and completed an additional 6 months of MAC therapy after reimplantation. | N 5 months                          | 77 (at time of resection) 8.7 (at time of resection) | One preoperative aspiration, two of two intraoperative |
| 4       | 77/F    | L   | hip  | RA treated with methotrexate and prednisone | PJJ occurred as part of a disseminated infection with MAC vertebral osteomyelitis and nodular bronchiectatic pulmonary MAC. Patient underwent lumbar spine surgical debridement and instrumentation. Patient developed L thigh and hip pain after 6 months of MAC therapy and was found to have L hip PJJ and retroperitoneal abscess. Repeat surgical cultures from hip explantation and debridement of abscess were positive for MAC. Patient underwent a one-stage exchange and remained on suppressive antibiotics. | Y 15 years                          | 95 (95)                                  | 4.0                                         | One positive culture from hip aspiration, other positive cultures at sites of dissemination |
| 5       | 46/F    | L   | knee | SLE treated with prednisone; refractory DLBCL, treated with R-ICE and Vanderbilt chemotherapy | Patient presented with L knee pain 1 year after L TKA while being treated for refractory diffuse large B-cell lymphoma. Knee aspirate grew both MAC and *Enterococcus faecium*. | Y 1 year                              | 63                                      | 46.5                                       | Two aspirations done on separate dates |

The abbreviations used in the table are as follows: AFB—acid-fast bacilli; MRI—magnetic resonance imaging; OA—osteoarthritis; PJI—prosthetic joint infection; DLBCL—diffuse large B-cell lymphoma; R-CHOP—rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-ICE—rituximab, ifosfamide, carboplatin, and etoposide; RA—rheumatoid arthritis; SLE—systemic lupus erythematosus; TKA—total knee arthroplasty; CRP—C-reactive protein; ESR—erythrocyte sedimentation rate; WBC—white blood cell; M—male; F—female; L—left; R—right. *At time of diagnosis. **At time of PJI diagnosis, relative to time of index implantation (if not otherwise specified). ^Prednisone, cyclophosphamide, etoposide, doxorubicin, vincristine, bleomycin, methotrexate, and leucovorin.
| Management | Patient | Cell count and differential | AFB smear/culture | Gross findings | Pathology | AFB smear/culture at surgery | Surgical management | Antimicrobial therapy | Outcome |
|------------|--------|-----------------------------|------------------|---------------|----------|----------------------------|-------------------|---------------------|---------|
| Antimicrobial therapy continued for 6 months post-implantation | 1 | 2120 (PMNs 10%, lymphocytes 24%, monocytes 66%) | Negative/MAC | Purulent joint fluid with caseous material | Not sent | Not done/MAC | Spacer exchange followed 8 months later by reimplantation of static weight-bearing spacer with tobramycin, vancomycin, and amphotericin; reimplantation done after 8 months on antibiotic therapy which continued for 8 months post-implantation | Ethambutol for 16 months, rifabutin for 16 months, and azithromycin for 16 months | Clinical cure of MAC PJI; recurrent PJI with Klebsiella aerogenes requiring resection arthroplasty 10 months post-reimplantation |
| Antimicrobial therapy continued for 6 months post-implantation | 2 | Not done (fluid obtained was of insufficient quantity for cell count) | Negative/MAC | Purulence and caseating granulomatous material throughout hip joint and thigh | Necrotizing tissue with foreign body giant cell reaction and chronic inflammation | Negative/MAC | Explantation without spacer placement; no reimplantation performed | Ethambutol, rifabutin, and azithromycin for 12 months (with a 2-month period during which azithromycin was inadvertently discontinued) | Delayed primary closure requiring return to OR, followed by subtrochanteric femur fracture; clinical cure at the 2-years follow-up (off antibiotics for 1 year) |
| Antimicrobial therapy continued for 6 months post-implantation | 3 | 26 964 (PMNs 77%, lymphocytes 12%, monocytes 11%) | Negative/MAC and Actinomyces neuii | Fragments of synovium with non-necrotizing granulomatous inflammation | Negative/MAC | Two-stage exchange: spacer with tobramycin, vancomycin, and amphotericin; reimplantation done after 8 months on antibiotic therapy which continued for 6 months post-implantation | Ethambutol and azithromycin for 15 months; rifabutin for 1 month, followed by rifampin for 14 months; ampicillin–sulbactam for 2 weeks, followed by penicillin G for 8 weeks, followed by amoxicillin–clavulanate for 12 months (for Actinomyces) | Clinical cure at the 2-year follow-up (off antibiotics for 10 months) |
| Antimicrobial therapy continued for 6 months post-implantation | 4 | 5764 (PMNs 7%, lymphocytes 10%, monocytes 83%) | Negative/MAC and Enterococcus faecium; repeat aspiration + MAC | NA | NA | NA | Surgery not done due to neutropenia and thrombocytopenia | Azithromycin and ethambutol for 4 months (until death), rifabutin (switched to rifampin after 1 month due to rifabutin shortage) for 4 months (until death) | Died 4 months after diagnosis due to refractory diffuse large B-cell lymphoma with central nervous system involvement |

The abbreviations used in the table are as follows: PMNs – polymorphonuclear leukocytes, MIC – minimum inhibitory concentration, S – susceptible, GI – gastrointestinal, and NA – not available.

*a* Identified on re-aspiration 2 months following initial aspiration for cell count/differential.

*b* Using broth dilution method.
tify patients at greatest risk of MAC PJI early in the disease course.

Clinicians should be aware of the potential for MAC to cause PJI in a variety of clinical contexts, and we would recommend sending AFB (acid-fast bacilli) cultures as part of the PJI workup among patients with RA or other immune-suppressing conditions as well as negative prior routine bacterial cultures.

**Ethical statement.** This research is performed with IRB approval or exemption: Stanford Health Care IRB no. 45840, 03/30/2018; Mayo IRB exemption 20-010933.

**Data availability.** Data for this project were obtained from the patients’ electronic medical records. No additional data are available.

**Author contributions.** All authors were involved with preparing and editing the manuscript. SK and KD were responsible for additional contributions towards case descriptions, summary, and analysis.

**Competing interests.** At least one of the (co-)authors is a member of the editorial board of Journal of Bone and Joint Infection. The peer-review process was guided by an independent editor, and the authors also have no other competing interests to declare.

**Disclaimer.** Publisher’s note: Copernicus Publications remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Acknowledgement.** This research used data or services provided by STARR (STAnford medicine Research data Repository), a clinical data warehouse containing live Epic data from Stanford Health Care, the Stanford Children’s Hospital, and the University Health care Alliance and Packard Children’s Health Alliance clinics as well as other auxiliary data from hospital applications such as radiology PACS (picture archiving and communications system). The STARR platform is developed and operated by the Stanford Medicine Research IT team and is made possible by the Stanford School of Medicine Research Office. We thank Niaz Banaei for his assistance describing microbiologic techniques and institutional protocol.

**Review statement.** This paper was edited by Alex Soriano Viladomiu and reviewed by two anonymous referees.

**References**

Daley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Andrejak, C., Bottger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., Huit, G. A., Knight, S. L., Leitman, P., Marras, T. K., Olivier, K. N., Santin, M., Stout, J. E., Tortoli, E., van Ingen, J., Wagner, D., and Winthrop, K. L.: Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline, Clin. Infect. Dis., 71, 905–913, https://doi.org/10.1093/cid/ciaa1125, 2020.

Gupta, A. and Clauss, H.: Prosthetic joint infection with Mycobacterium avium complex in a solid organ transplant recipient, Transpl. Infect. Dis., 11, 537–540, https://doi.org/10.1111/j.1399-3062.2009.00433.x, 2009.

Ingraham, N. E., Schneider, B., and Alpern, J. D.: Prosthetic Joint Infection due to Mycobacterium avium-intracellulare in a Patient with Rheumatoid Arthritis: A Case Report and Review of the Literature, Case Rep. Infect. Dis., 2017, 8682354, https://doi.org/10.1155/2017/8682354, 2017.

McLaughlin, J. R., Tierney, M., and Harris, W. H.: Mycobacterium avium intracellular infection of hip arthroplasties in an AIDS patient, J. Bone Joint Surg. Br., 76, 498–499, 1994.

Osmon, D. R., Berbari, E. F., Berendt, A. R., Lew, D., Zimmerli, W., Steckelberg, J. M., Rao, N., Hanssen, A., Wilson, W. R., and Infectious Diseases Society of America: Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America, Clin. Infect. Dis., 56, e1–e25, https://doi.org/10.1093/cid/cis803, 2013.

Sigler, R. and Newman, J. R.: Mycobacterium Avium Prosthetic Hip Infection on Abatacept Presenting as Fever of Unknown Origin, J. Bone Joint Infect., 4, 194–197, https://doi.org/10.7150/jbji.35703, 2019.

Sixt, T., Bador, J., Amoureux, L., Piroth, L., and Blot, M.: Prosthetic joint infection caused by Mycobacterium avium complex, Queensland Journal of Medicine, 113, 278–279, https://doi.org/10.1093/qjmed/hcz306, 2020.

Tan, E. M., Marcelin, J. R., Mason, E., and Virk, A.: Mycobacterium avium intracellular complex causing olecranon bursitis and prosthetic joint infection in an immunocompromised host, J. Clin. Tuberc. Other Mycobact. Dis., 2, 1–4, https://doi.org/10.1016/j.jctube.2015.11.003, 2016.

Workgroup Convened by the Musculoskeletal Infection Society: New definition for periprosthetic joint infection, J. Arthroplasty, 26, 1136–1138, https://doi.org/10.1016/j.arth.2011.09.026, 2011.